Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Multiple Myeloma|Breast Cancer
Interventions: DRUG: Zoledronic acid
Sponsor: Novartis Pharmaceuticals